• Director Wendall Wierenga sold 20,000 shares at $38.46, reducing his holdings to 24,848 shares.
• The company granted stock options and RSUs to new employees, aligning with Nasdaq Listing Rule 5635(c)(4).
• CYTK's stock price saw a 3.93% decrease to $37.93, amidst a volatile trading year.

Cytokinetics, Incorporated (NASDAQ:CYTK), trades on the Nasdaq and is known for its focus on developing muscle biology-driven treatments for diseases such as heart failure and amyotrophic lateral sclerosis (ALS). Competing with biotech giants like Amgen and Biogen, Cytokinetics recently saw a significant transaction by director Wierenga Wendall, who sold 20,000 shares at $38.46 each, leaving him with 24,848 shares.

On April 15, 2025, Cytokinetics granted stock options and restricted stock units (RSUs) to new employees. The company issued options for 60,670 shares and 40,888 RSUs. These RSUs will vest over three years, with 40% vesting on the first and second anniversaries, and 20% on the third, contingent on continued employment.

The stock options have an exercise price of $38.56, matching the closing price on the grant date. They will vest over four years, in compliance with Nasdaq Listing Rule 5635(c)(4), which permits companies to issue equity compensation to new employees as an inducement for employment.

CYTK's current stock price is $37.93, reflecting a 3.93% decrease, with a $1.55 drop. The stock's trading range for the day was between $37.45 and $39.15. Over the past year, CYTK has experienced a high of $68.76 and a low of $32.74, indicating significant volatility in its stock price.

Cytokinetics' market capitalization is approximately $4.52 billion, with a trading volume of 1,850,572 shares on the Nasdaq exchange. This market cap reflects the company's overall value, calculated by multiplying the current stock price by the total number of outstanding shares.